The American Diabetes Association guidelines, together with International recommendations from other prestigious societies and expert panels, suggest that for patients with T2DM and CardioVascular Disease (CVD) or Chronic Kidney Disease (CKD) the addition of Sodium–Glucose Cotransporter 2 (SGTL2) inhibitors and/or Glucagon-Like Peptide 1 Receptor agonists (GLP1-Ras) should be considered as first-line therapy [17,18,19]; indeed, these agents should be used not only to lower HbA1c, but also for improvement of the patient’s general cardio-renal-metabolic condition [19]. This evidence concerns the gene GCG and chronic kidney disease.